Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verteporfin PDT for Multiple Basal Cell Carcinoma
NCT00049959Phase 3Terminated
- Sponsor
- QLT Inc.
- Primary completion
- Mar 2004
- Modality
- Light/Condition-Responsive Prodrugs
01
Overview
Phase 3, randomised, double-blind trial in basal cell carcinoma (BCC) comparing Verteporfin PDT with Placebo PDT (2 arms). Primary endpoint: Complete Elimination of Basal Cell Carcinoma at 6 months. Status: terminated.
02
Drugs
verteporfin
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT00049959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00049959.